Revolution Medicines announces positive results from the Phase 1b clinical trial of its investigational pan-RAS inhibitor RMC-6236

Revolution Medicines announced positive results from the Phase 1b clinical trial of its investigational pan-RAS inhibitor RMC-6236. Analysis showed that as a second-line therapy, RMC-6236 can extend the median progression-free survival of patients with KRAS G12X mutations to 8.1 months and achieve a disease control rate of nearly 90%. The company plans to conduct a global randomized Phase 3 clinical trial, using RMC-6236 as a second-line therapy for PDAC patients. This drug is the first targeted investigational therapy for all major RAS mutation types, which is of significant importance in addressing the key drivers of PDAC disease progression